Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer
Platinum-based chemotherapy is still the standard of care after cytoreductive surgery in the first-line treatment for epithelial ovarian cancer. This study aims to integrate novel biomarkers for predicting platinum sensitivity in EOC after initial cytoreductive surgery precisely. To this end, 60 pat...
Main Authors: | Hong Zheng, Tong Shu, Shan Zhu, Chao Zhang, Min Gao, Nan Zhang, Hongguo Wang, Jie Yuan, Zaixian Tai, Xuefeng Xia, Yuting Yi, Jin Li, Yanfang Guan, Yang Xiang, Yunong Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.725264/full |
Similar Items
-
miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer
by: Xiaotang Yu, et al.
Published: (2020-11-01) -
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
by: Cui Q, et al.
Published: (2021-01-01) -
Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
by: Mohamed Elshebeiny, et al.
Published: (2016-09-01) -
An Update on Ovarian Aging and Ovarian Reserve Tests
by: Ramazan Amanvermez, et al.
Published: (2016-01-01) -
Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining
by: Haixia Li, et al.
Published: (2020-03-01)